Answers are grounded in this paper and cite their sources.
This case highlights the phenotype and the limited response to GH in a child with genetically proven KCS type 2. Long-term registries monitoring growth outcomes following GH therapy in patients with rare genetic conditions may help guide clinical decisions regarding the use and doses of GH in these conditions.
No takes yet. Share an insight, caveat, or question.
Abraham et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: